Search

Your search keyword '"Brusselle, G."' showing total 566 results
Start Over Author "Brusselle, G."
566 results on '"Brusselle, G."'

2. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

Author

Bousquet, J., Sousa-Pinto, B., Anto, J.M., Amaral, R., Brussino, L., Canonica, G.W., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Louis, R., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., Chaves-Loureiro, C., Czarlewski, W., de Blay, F., Devillier, P., Joos, G., Jutel, M., Klimek, L., Kuna, P., Laune, D., Pech, J.L., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Ohta, K., Papadopoulos, N.G., Papi, A., Yeverino, D.R., Roche, N., Sá-Sousa, A., Samolinski, B., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Vandenplas, O., Yorgancioglu, A., Zuberbier, T., and Fonseca, J.A.

Published
2023
Full Text
View/download PDF

3. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Author

Sousa-Pinto, B., Louis, R., Anto, J.M., Amaral, R., Sá-Sousa, A., Czarlewski, W., Brussino, L., Canonica, G.W., Chaves Loureiro, C., Cruz, A.A., Gemicioglu, B., Haahtela, T., Kupczyk, M., Kvedariene, V., Larenas-Linnemann, D.E., Okamoto, Y., Ollert, M., Pfaar, O., Pham-Thi, N., Puggioni, F., Regateiro, F.S., Romantowski, J., Sastre, J., Scichilone, N., Taborda-Barata, L., Ventura, M.T., Agache, I., Bedbrook, A., Becker, S., Bergmann, K.C., Bosnic-Anticevich, S., Bonini, M., Boulet, L.-P., Brusselle, G., Buhl, R., Cecchi, L., Charpin, D., de Blay, F., Del Giacco, S., Ivancevich, J.C., Jutel, M., Klimek, L., Kraxner, H., Kuna, P., Laune, D., Makela, M., Morais-Almeida, M., Nadif, R., Niedoszytko, M., Papadopoulos, N.G., Papi, A., Patella, V., Pétré, B., Rivero Yeverino, D., Robalo Cordeiro, C., Roche, N., Rouadi, P.W., Samolinski, B., Savouré, M., Shamji, M.H., Sheikh, A., Suppli Ulrik, C., Usmani, O.S., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Fonseca, J.A., Costa, E.M., and Bousquet, J.

Published
2023
Full Text
View/download PDF

5. Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis

Author

Couillard, S., primary, Meulmeester, F.L., additional, Celis-Preciado, C.A., additional, Ramakrishnan, S., additional, Brusselle, G., additional, Corren, J., additional, Hardy, J., additional, Diver, S.E., additional, Brightling, C.E., additional, Castro, M., additional, Hanania, N.A., additional, Wechsler, M.E., additional, Jackson, D.J., additional, Martin, N., additional, Clarke, D., additional, Laugerud, A., additional, Santoro, E., additional, Compton, C., additional, Hardin, M.E., additional, Holweg, C.T.J., additional, Jaumont, X., additional, Hinks, T.S.C., additional, Beasley, R.W., additional, Sont, J.K., additional, Steyerberg, E.W., additional, and Pavord, I.D., additional

Published
2024
Full Text
View/download PDF

6. Impact of Atopic Status, Prior Omalizumab Use and Baseline Blood Eosinophil Count Alone and in Combination With Total Serum IgE on Maintenance OCS Reduction Outcomes in Patients With Severe Asthma Treated With Mepolizumab in the REALITI-A Study

Author

Liu, M.C., primary, Chaudhuri, R., additional, Chupp, G.L., additional, Heaney, L.G., additional, Lee, J.K., additional, Pilette, C., additional, Brusselle, G., additional, Alfonso Cristancho, R., additional, Zhang, L., additional, and Howarth, P., additional

Published
2024
Full Text
View/download PDF

7. Flemish network on rare connective tissue diseases (CTD):patient pathways in systemic sclerosis. First steps taken

Author

Piette, Y., Van den Bossche, F., Aerts, J., Aerts, N., Ajeganova, S., Badot, V., Berghen, N., Blockmans, D., Brusselle, G., Caeyers, N., De Decker, M., De Haes, P., De Cock, C., De Keyser, F., De Langhe, E., Delcroix, M., De Nutte, H., De Pauw, M., Depicker, A., De Sutter, A., De Sutter, J., Du Four, T., Frank, C., Goubau, J., Guiot, J., Gutermuth, J., Heeman, L., Houssiau, F., Hennes, I., Lenaerts, J., Lintermans, A., Loeys, B., Luyten, H., Maeyaert, B., Malfait, F., Moeyersoons, A., Mostmans, Y., Nijs, J., Poppe, B., Polfliet, K., Ruttens, D., Sabato, V., Schoeters, E., Slabbynck, H., Stuer, A., Tamirou, F., Thevissen, Kristof, Van Kersschaever, G., Vanneuville, B., Van Offel, J., Vanthuyne, M., Van Wabeke, J., Verbist, C., Vos, I., Westhovens, R., Wuyts, W., Yserbyt, J., Smith, V., Piette, Y., Van den Bossche, F., Aerts, J., Aerts, N., Ajeganova, S., Badot, V., Berghen, N., Blockmans, D., Brusselle, G., Caeyers, N., De Decker, M., De Haes, P., De Cock, C., De Keyser, F., De Langhe, E., Delcroix, M., De Nutte, H., De Pauw, M., Depicker, A., De Sutter, A., De Sutter, J., Du Four, T., Frank, C., Goubau, J., Guiot, J., Gutermuth, J., Heeman, L., Houssiau, F., Hennes, I., Lenaerts, J., Lintermans, A., Loeys, B., Luyten, H., Maeyaert, B., Malfait, F., Moeyersoons, A., Mostmans, Y., Nijs, J., Poppe, B., Polfliet, K., Ruttens, D., Sabato, V., Schoeters, E., Slabbynck, H., Stuer, A., Tamirou, F., Thevissen, Kristof, Van Kersschaever, G., Vanneuville, B., Van Offel, J., Vanthuyne, M., Van Wabeke, J., Verbist, C., Vos, I., Westhovens, R., Wuyts, W., Yserbyt, J., and Smith, V.

Abstract

Despite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.

Published
2024

8. Obtention d’une rémission clinique dans l’asthme sévère après un traitement par mépolizumab : résultats de l’étude REALITI-A à 2 ans

Author

Brusselle, G., primary, Lougheed, D., additional, Canonica, G.W., additional, Munoz-Esquerre, M., additional, Heaney, L.G., additional, Price, R.G., additional, Howarth, P., additional, Raimondi, A., additional, Gardiner, F., additional, Chupp, G., additional, Welte, T., additional, and Picaud, C., additional

Published
2024
Full Text
View/download PDF

9. Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken

Author

Piette, Y., primary, Van den Bossche, F., additional, Aerts, J., additional, Aerts, N., additional, Ajeganova, S., additional, Badot, V., additional, Berghen, N., additional, Blockmans, D., additional, Brusselle, G., additional, Caeyers, N., additional, De Decker, M., additional, De Haes, P., additional, De Cock, C., additional, De Keyser, F., additional, De Langhe, E., additional, Delcroix, M., additional, De Nutte, H., additional, De Pauw, M., additional, Depicker, A., additional, De Sutter, A., additional, De Sutter, J., additional, Du Four, T., additional, Frank, C., additional, Goubau, J., additional, Guiot, J., additional, Gutermuth, J., additional, Heeman, L., additional, Houssiau, F., additional, Hennes, I., additional, Lenaerts, J., additional, Lintermans, A., additional, Loeys, B., additional, Luyten, H., additional, Maeyaert, B., additional, Malfait, F., additional, Moeyersoons, A., additional, Mostmans, Y., additional, Nijs, J., additional, Poppe, B., additional, Polfliet, K., additional, Ruttens, D., additional, Sabato, V., additional, Schoeters, E., additional, Slabbynck, H., additional, Stuer, A., additional, Tamirou, F., additional, Thevissen, Kristof, additional, Van Kersschaever, G., additional, Vanneuville, B., additional, Van Offel, J., additional, Vanthuyne, M., additional, Van Wabeke, J., additional, Verbist, C., additional, Vos, I., additional, Westhovens, R., additional, Wuyts, W., additional, Yserbyt, J., additional, and Smith, V., additional

Published
2023
Full Text
View/download PDF

11. Toward effective prescription of inhaled corticosteroids in chronic airway disease

Author

Diamant Z, Brusselle G, and Russell RE

Subjects
asthma, COPD, Diseases of the respiratory system, RC705-779
Abstract

Zuzana Diamant,1–3 Guy Brusselle,4 Richard E Russell5,6 1Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 2Department of Clinical Pharmacy & Pharmacology University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands; 3QPS-Netherlands, University Medical Centre Groningen, Groningen, the Netherlands; 4Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 5Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK; 6Lymington New Forest Hospital, Southern Health National Health Service Foundation Trust, Lymington, Hampshire, UKThe airway diseases asthma and COPD affect millions of individuals worldwide.1 These diseases are major determinants of chronic morbidity and mortality, and represent a substantial public health burden.2–4 Despite differences in etiology, clinical characteristics, and pathophysiology, both conditions share important features, such as airway obstruction and chronic airway inflammation. As a result of modern lifestyle, the incidence of both diseases is steadily increasing worldwide and effective preventive and treatment strategies are unmet needs.5

Published
2018

15. Dupilumab Induces Clinical Remission in Patients With Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma

Author

Pavord, I.D., primary, Israel, E., additional, Szefler, S.J., additional, Brusselle, G., additional, Rabe, K.F., additional, Chen, Z., additional, Altincatal, A., additional, Radwan, A., additional, Pandit-Abid, N., additional, Amin, N., additional, Jacob-Nara, J.A., additional, Rowe, P.J., additional, Deniz, Y.M., additional, Khan, A., additional, Lederer, D.J., additional, Zhang, Y., additional, and Busse, W., additional

Published
2023
Full Text
View/download PDF

17. La FeNO, un marqueur pronostique et prédictif potentiel de déclin de la fonction respiratoire chez des patients atteints d’asthme modéré à sévère non contrôlé : LIBERTY ASTHMA QUEST

Author

Pavord, I.D., primary, Berger, P., additional, Brusselle, G., additional, Jackson, D.J., additional, Brightling, C.E., additional, Papi, A., additional, Maspero, J.F., additional, Rabe, K.F., additional, Korn, S., additional, Zhang, M., additional, Djandji, M., additional, Hardin, M., additional, Gómez, L.D.P., additional, Jacob-Nara, J.A., additional, and Rowe, P.J., additional

Published
2023
Full Text
View/download PDF

18. CO54 Dupilumab vs Placebo Improves Symptoms, Asthma Control, and Asthma-Related Quality of Life in Patients With Oral Corticosteroid-Dependent Severe Asthma Through 48 Weeks of Follow up

Author

Gurnell, M, primary, Domingo, C, additional, Rabe, KF, additional, Menzies-Gow, A, additional, Price, D, additional, Brusselle, G, additional, Wechsler, ME, additional, Xia, C, additional, Pandit-Abid, N, additional, Gall, R, additional, Jacob-Nara, JA, additional, Rowe, PJ, additional, Siddiqui, S, additional, and Deniz, Y, additional

Published
2022
Full Text
View/download PDF

19. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

Author

Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Faison, S., Padilla, K., Martin, U. J., Gil, E. G., Ardusso, L., Bazerque, R. F., Doreski, P. A. C., Elias, P. C., Gattolin, G., Medina, A. C., Ruiz, X. B., Salvado, A., Del Olmo Sansone, R. A., Wehbe, L., Verra, F. J. B., Brusselle, G., Pilette, C., Martinot, J. -B., Antila, M. A., Blanco, D. C., Cerci, A., Cunha, T. M., Fiss, E., Franza, L., Machado, A. S., De Mattos, W. L. L. D., Grava, S., Minamoto, S. E. T., De Oliveira, C. A., Cheema, A. S., Dorscheid, D., Fera, T. A. E., Gagnon, R., Philteos, G., Sussman, G., Yang, W. H. -C., Aguilar, C. D., Jaller, R., Jazime, M. L., Serrano, F. O., Vanegas, A. C., Vargas, L. K., Villegas, M. F., Hilberg, O., Nielsen, H. B., Nielsen, J., Weinreich, U. M., Ulrik, C. S., Adam, S. M., Deslee, G., Pegliasco, H., Pradelli, J., Roux, P. -M., Russier, M., Deckelmann, R., Eich, A., Forster, A., Herth, F., Kirschner, J., Kirsten, A. -M., Schuhmann, M., Schultz, T. K., Ludwig-Sengpiel, A., Teber, I., Zimmermann, G. S., Almerigogna, F., Celi, A., Paggiaro, P., D'Amato, M., Palange, P., Pirina, P., Spanevello, A., Colin, D. D. H., Hernandez, A. R., Garcia, E. A. R., Gonzalez, E. M., Terrones, R. A. R., Javier, R. C., Suarez, J. F. R., Cheimihska, M., Cudzik, K., Olech-Cudzik, A., Filipek, K., Golinski, L., Kwasniewski, A., Madra-Rogacka, D., Mroz, R., Nittner-Marszalska, M., Pawlukiewicz, M., Lekarska, P. P., Pioszczuk, A., Springer, E., Swiderska, A., Zurowska-Gebala, M., Emelyanov, A. V., Kurbacheva, O., Odegova, A., Peskov, A., Petrov, D. V., Rubanik, T. V., Vasilev, M., Vershinina, M., Barcala, F. J. G., Blanco, V. R., Fernandez, A. M. P., Fernandez, C. G., Garcia, J. M. I., Munoz, A. V. A., Ramos, C. C., Sanz, C. C., Bjermer, L., Chen, C. -Y., Fang, W. -F., Hang, L. -W., Hsu, J. -Y., Kuo, H. -P., Lee, K. -Y., Shen, S. -Y., Sheu, C. -C., Gore, R., Saralaya, D., Alpizar, S. A., Bansal, S., Ismail, H., Kaelin, T. D., Koura, F., Lee, M. D., Maddipati, V., Malur, A., Mcevoy, C. E., Mehta, H., Mohan, A., Moore, W. C., Krings, J., Pippins, A., Deaton, I., Hmieleski, B., Field, P., Reibman, J., Siri, D. D., Sumino, K., Swenson, C., Tilley, S. L., Villareal, M., Pulmonology, and Pulmonary medicine

Subjects
Pulmonary and Respiratory Medicine, Adrenal Cortex Hormones, Humans, Anti-Asthmatic Agents, Recovery of Function, Asthma, Adrenal Insufficiency
Abstract

BackgroundOral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day−1(median (range) 0.0 (0.0–40.0) mg).MethodsThe maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ∼6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events.Results598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0–40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (–19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.ConclusionsMost patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.

Published
2022

21. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK

Author

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, Baldwin M, and Jones RC

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Guy Brusselle,1–3 David Price,4,5 Kevin Gruffydd-Jones,6 Marc Miravitlles,7 Dorothy L Keininger,8 Rebecca Stewart,5 Michael Baldwin,9 Rupert C Jones101Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium; 2Department of Epidemiology, 3Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, Netherlands; 4Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK; 5Research in Real Life (RiRL), Singapore; 6Box Surgery, Wiltshire, UK; 7Pneumology Department, Hospital Universitari Vall d’Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 8Novartis Pharma AG, Basel, Switzerland; 9Novartis Pharmaceuticals Limited, Horsham, UK; 10Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UKBackground: Real-world prescription pathways leading to triple therapy (TT) (inhaled corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting muscarinic antagonist) differ from Global initiative for chronic Obstructive Lung Disease [GOLD] and National Institute for Health and Care Excellence treatment recommendations. This study sets out to identify COPD patients without asthma receiving TT, and determine the pathways taken from diagnosis to the first prescription of TT.Methods: This was a historical analysis of COPD patients without asthma from the Optimum Patient Care Research Database (387 primary-care practices across the UK) from 2002 to 2010. Patient disease severity was classified using GOLD 2013 criteria. Data were analyzed to determine prescribing of TT before, at, and after COPD diagnosis; the average time taken to receive TT; and the impact of lung function grade, modified Medical Research Council dyspnea score, and exacerbation history on the pathway to TT.Results: During the study period, 32% of patients received TT. Of these, 19%, 28%, 37%, and 46% of patients classified as GOLD A, B, C, and D, respectively, progressed to TT after diagnosis (P

Published
2015

24. Validation of Clinical COPD Phenotypes for Prognosis of Long-Term Mortality in Swedish and Dutch Cohorts

Author

Gagatek, S., primary, Wijnant, S. R. A., additional, Ställberg, B., additional, Lisspers, K., additional, Brusselle, G., additional, Zhou, X., additional, Hasselgren, M., additional, Montgomeryi, S., additional, Sundhj, J., additional, Janson, C., additional, Emilsson, Ö., additional, Lahousse, L., additional, and Malinovschi, A., additional

Published
2022
Full Text
View/download PDF

30. Biomarkers associated with lung function decline and dupilumab response in patients with moderate-to-severe asthma

Author

Pavord, I D, primary, Brusselle, G, additional, Jackson, D J, additional, Brightling, C E, additional, Papi, A, additional, Maspero, J F, additional, Rabe, K F, additional, Korn, S, additional, Zhang, M, additional, Pandit-Abid, N, additional, Hardin, M, additional, De Prado Gómez, L, additional, Jacob-Nara, J A, additional, and Rowe, P J, additional

Published
2022
Full Text
View/download PDF

33. Multi-ancestral meta-analysis yields novel genetic loci for asthma exacerbations

Author

Herrera Luis, E, primary, Ortega, V E, additional, Ampleford, E J, additional, Sio, Y Y, additional, Granell, R, additional, De Roos, E, additional, Terzikhan, N, additional, Elorduy Vergara, E, additional, Hernandez-Pacheco, N, additional, Perez-Garcia, J, additional, Martin-Gonzalez, E, additional, Lorenzo-Diaz, F, additional, Hashimoto, S, additional, Brinkman, P, additional, Jorgensen, A L, additional, Yan, Q, additional, Forno, E, additional, Vijverberg, S J, additional, Lethem, R, additional, Espuela-Ortiz, A, additional, Gorenjak, M, additional, Eng, C, additional, González-Pérez, R, additional, Hernández-Pérez, J M, additional, Poza-Guedes, P, additional, Sardón, O, additional, Corcuera, P, additional, Hawkins, G A, additional, Marsico, A, additional, Bahmer, T, additional, Rabe, K F, additional, Hansen, G, additional, Kopp, M V, additional, Rios, R, additional, Cruz, M J, additional, González-Barcala, F, additional, Olaguibel, J M, additional, Plaza, V, additional, Quirce, S, additional, Canino, G, additional, Cloutier, M, additional, Del Pozo, V, additional, Rodriguez-Santana, J R, additional, Korta-Murua, J, additional, Villar, J, additional, Potočnik, U, additional, Figueiredo, C, additional, Kabesch, M, additional, Mukhopadhyay, S, additional, Pirmohamed, M, additional, Hawcutt, D B, additional, Melén, E, additional, Palmer, C N, additional, Turner, S, additional, Maitland-Van Der Zee, A H, additional, Von Mutius, E, additional, Celedón, J C, additional, Brusselle, G, additional, Chew, F T, additional, Bleecker, E, additional, Meyers, D, additional, G Burchard, E, additional, and Pino-Yanes, M, additional

Published
2022
Full Text
View/download PDF

34. Pulmonologists collaborate with explainable artificial intelligence for superior interpretation of pulmonary function tests

Author

Das, N, primary, Happaerts, S, additional, Dinh-Xuan, A T, additional, Vanderelst, E, additional, Haenebalcke, C, additional, Brusselle, G, additional, Derom, E, additional, Burgos, F, additional, Franssen, F, additional, Watz, H, additional, Quint, J, additional, Moises, J, additional, Contoli, M, additional, Steiner, M, additional, Greening, N, additional, Peché, R, additional, Gonem, S, additional, Poberezhets, V, additional, Mann, W, additional, Topalovic, M, additional, and Janssens, W, additional

Published
2022
Full Text
View/download PDF

41. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns

Author

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, and Bichel K

Subjects
Diseases of the respiratory system, RC705-779
Abstract

David Price,1 Daniel West,2 Guy Brusselle,3–5 Kevin Gruffydd-Jones,6 Rupert Jones,7 Marc Miravitlles,8 Andrea Rossi,9 Catherine Hutton,2 Valerie L Ashton,2 Rebecca Stewart,2 Katsiaryna Bichel2 1Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK; 2Research in Real-Life Ltd, Cambridge, UK; 3Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 4Department of Epidemiology, 5Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; 6Box Surgery, Wiltshire, UK; 7Centre for Clinical Trials and Health Research – Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth UK; 8Department of Pneumology, Hospital Universitari Vall d'Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 9Pulmonary Unit, Cardiovascular and Thoracic Department, University and General Hospital, Verona, Italy Background: Despite the availability of national and international guidelines, evidence suggests that chronic obstructive pulmonary disease (COPD) treatment is not always prescribed according to recommendations. This study evaluated the current management of patients with COPD using a large UK primary-care database. Methods: This analysis used electronic patient records and patient-completed questionnaires from the Optimum Patient Care Research Database. Data on current management were analyzed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) group and presence or absence of a concomitant asthma diagnosis, in patients with a COPD diagnosis at ≥35 years of age and with spirometry results supportive of the COPD diagnosis. Results: A total of 24,957 patients were analyzed, of whom 13,557 (54.3%) had moderate airflow limitation (GOLD Stage 2 COPD). The proportion of patients not receiving pharmacologic treatment for COPD was 17.0% in the total COPD population and 17.7% in the GOLD Stage 2 subset. Approximately 50% of patients in both cohorts were receiving inhaled corticosteroids (ICS), either in combination with a long-acting β2-agonist (LABA; 26.7% for both cohorts) or a LABA and a long-acting muscarinic antagonist (LAMA; 23.2% and 19.9%, respectively). ICS + LABA and ICS + LABA + LAMA were the most frequently used treatments in GOLD Groups A and B. Of patients without concomitant asthma, 53.7% of the total COPD population and 50.2% of the GOLD Stage 2 subset were receiving ICS. Of patients with GOLD Stage 2 COPD and no exacerbations in the previous year, 49% were prescribed ICS. A high proportion of GOLD Stage 2 COPD patients were symptomatic on their current management (36.6% with modified Medical Research Council score ≥2; 76.4% with COPD Assessment Test score ≥10). Conclusion: COPD is not treated according to GOLD and National Institute for Health and Care Excellence recommendations in the UK primary-care setting. Some patients receive no treatment despite experiencing symptoms. Among those on treatment, most receive ICS irrespective of severity of airflow limitation, asthma diagnosis, and exacerbation history. Many patients on treatment continue to have symptoms. Keywords: COPD, UK primary-care setting, prescribing patterns, inhaled corticosteroids, bronchodilators

Published
2014

44. Validation of Clinical COPD Phenotypes for Prognosis of Long-Term Mortality in Swedish and Dutch Cohorts

Author

Gagatek, Sebastian, Wijnant, S. R. A., Ställberg, Björn, Lisspers, Karin, Brusselle, G., Zhou, Xingwu, Hasselgren, M., Montgomery, S., Sundhj, J., Janson, Christer, Emilsson, Össur Ingi, Lahousse, L., Malinovschi, Andrei, Gagatek, Sebastian, Wijnant, S. R. A., Ställberg, Björn, Lisspers, Karin, Brusselle, G., Zhou, Xingwu, Hasselgren, M., Montgomery, S., Sundhj, J., Janson, Christer, Emilsson, Össur Ingi, Lahousse, L., and Malinovschi, Andrei

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with variable mortality risk. The aim of our investigation was to validate a simple clinical algorithm for long-term mortality previously proposed by Burgel et al. in 2017. Subjects with COPD from two cohorts, the Swedish PRAXIS study (n = 784, mean age (standard deviation (SD)) 64.0 years (7.5), 42% males) and the Rotterdam Study (n = 735, mean age (SD) 72 years (9.2), 57% males), were included. Five clinical clusters were derived from baseline data on age, body mass index, dyspnoea grade, pulmonary function and comorbidity (cardiovascular disease/diabetes). Cox models were used to study associations with 9-year mortality. The distribution of clinical clusters (1-5) was 29%/45%/8%/6%/12% in the PRAXIS study and 23%/26%/36%/0%/15% in the Rotterdam Study. The cumulative proportion of deaths at the 9-year follow-up was highest in clusters 1 (65%) and 4 (72%), and lowest in cluster 5 (10%) in the PRAXIS study. In the Rotterdam Study, cluster 1 (44%) had the highest cumulative mortality and cluster 5 (5%) the lowest. Compared with cluster 5, the meta-analysed age- and sex-adjusted hazard ratio (95% confidence interval) for cluster 1 was 6.37 (3.94-10.32) and those for clusters 2 and 3 were 2.61 (1.58-4.32) and 3.06 (1.82-5.13), respectively. Burgel's clinical clusters can be used to predict long-term mortality risk. Clusters 1 and 4 are associated with the poorest prognosis, cluster 5 with the best prognosis and clusters 2 and 3 with intermediate prognosis in two independent cohorts from Sweden and the Netherlands.

Published
2022
Full Text
View/download PDF

45. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J, Sousa-Pinto, B, Anto, J M, Amaral, R, Brussino, L, Canonica, G W, Cruz, A A, Gemicioglu, B, Haahtela, T, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Louis, R, Pham-Thi, N, Puggioni, F, Regateiro, F S, Romantowski, J, Sastre, J, Scichilone, N, Taborda-Barata, L, Ventura, M T, Agache, I, Bedbrook, A, Bergmann, K C, Bosnic-Anticevich, S, Bonini, M, Boulet, L-P, Brusselle, G, Buhl, R, Cecchi, L, Charpin, D, Chaves-Loureiro, C, Czarlewski, W, de Blay, F, Devillier, P, Joos, G, Jutel, M, Klimek, L, Kuna, P, Laune, D, Pech, J L, Makela, M, Morais-Almeida, M, Nadif, R, Niedoszytko, M, Ohta, K, Papadopoulos, N G, Papi, A, Yeverino, D R, Roche, N, Sá-Sousa, A, Samolinski, B, Shamji, M H, Sheikh, A, Suppli Ulrik, C, Usmani, O S, Valiulis, A, Vandenplas, Olivier, Yorgancioglu, A, Zuberbier, T, Fonseca, J A, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J, Sousa-Pinto, B, Anto, J M, Amaral, R, Brussino, L, Canonica, G W, Cruz, A A, Gemicioglu, B, Haahtela, T, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Louis, R, Pham-Thi, N, Puggioni, F, Regateiro, F S, Romantowski, J, Sastre, J, Scichilone, N, Taborda-Barata, L, Ventura, M T, Agache, I, Bedbrook, A, Bergmann, K C, Bosnic-Anticevich, S, Bonini, M, Boulet, L-P, Brusselle, G, Buhl, R, Cecchi, L, Charpin, D, Chaves-Loureiro, C, Czarlewski, W, de Blay, F, Devillier, P, Joos, G, Jutel, M, Klimek, L, Kuna, P, Laune, D, Pech, J L, Makela, M, Morais-Almeida, M, Nadif, R, Niedoszytko, M, Ohta, K, Papadopoulos, N G, Papi, A, Yeverino, D R, Roche, N, Sá-Sousa, A, Samolinski, B, Shamji, M H, Sheikh, A, Suppli Ulrik, C, Usmani, O S, Valiulis, A, Vandenplas, Olivier, Yorgancioglu, A, Zuberbier, T, and Fonseca, J A

Abstract

The self-reporting of asthma frequently leads to patient misidentification in epidemiological studies. Strategies combining the triangulation of data sources may help to improve the identification of people with asthma. We aimed to combine information from the self-reporting of asthma, medication use and symptoms to identify asthma patterns in the users of an mHealth app. We studied MASK-air® users who reported their daily asthma symptoms (assessed by a 0-100 visual analogue scale - "VAS Asthma") at least three times (either in three different months or in any period). K-means cluster analysis methods were applied to identify asthma patterns based on: (i) whether the user self-reported asthma; (ii) whether the user reported asthma medication use and (iii) VAS asthma. Clusters were compared by the number of medications used, VAS asthma levels and Control of Asthma and Allergic Rhinitis Test (CARAT) levels. We assessed a total of 8,075 MASK-air® users. The main clustering approach resulted in the identification of seven groups. These groups were interpreted as probable: (i) severe/uncontrolled asthma despite treatment (11.9-16.1% of MASK-air® users); (ii) treated and partly-controlled asthma (6.3-9.7%); (iii) treated and controlled asthma (4.6-5.5%); (iv) untreated uncontrolled asthma (18.2-20.5%); (v) untreated partly-controlled asthma (10.1-10.7%); (vi) untreated controlled asthma (6.7-8.5%) and (vii) no evidence of asthma (33.0-40.2%). This classification was validated in a study of 192 patients enrolled by physicians. We identified seven profiles based on the probability of having asthma and on its level of control. mHealth tools are hypothesis-generating and complement classical epidemiological approaches in identifying patients with asthma.

Published
2022

46. Genetic Associations and Architecture of Asthma-COPD Overlap:Chest

Author

John, C., Guyatt, A. L., Shrine, N., Packer, R., Olafsdottir, T. A., Liu, J., Hayden, L. P., Chu, S. H., Koskela, J. T., Luan, J., Li, X., Terzikhan, N., Xu, H., Bartz, T. M., Petersen, H., Leng, S., Belinsky, S. A., Cepelis, A., Hernández Cordero, A. I., Obeidat, M., Thorleifsson, G., Meyers, D. A., Bleecker, E. R., Sakoda, L. C., Iribarren, C., Tesfaigzi, Y., Gharib, S. A., Dupuis, J., Brusselle, G., Lahousse, L., Ortega, V. E., Jonsdottir, I., Sin, D. D., Bossé, Y., van den Berge, M., Nickle, D., Quint, J. K., Sayers, I., Hall, I. P., Langenberg, C., Ripatti, S., Laitinen, T., Wu, A. C., Lasky-Su, J., Bakke, P., Gulsvik, A., Hersh, C. P., Hayward, C., Langhammer, A., Brumpton, B., Stefansson, K., Cho, M. H., Wain, L. V., Tobin, M. D., John, C., Guyatt, A. L., Shrine, N., Packer, R., Olafsdottir, T. A., Liu, J., Hayden, L. P., Chu, S. H., Koskela, J. T., Luan, J., Li, X., Terzikhan, N., Xu, H., Bartz, T. M., Petersen, H., Leng, S., Belinsky, S. A., Cepelis, A., Hernández Cordero, A. I., Obeidat, M., Thorleifsson, G., Meyers, D. A., Bleecker, E. R., Sakoda, L. C., Iribarren, C., Tesfaigzi, Y., Gharib, S. A., Dupuis, J., Brusselle, G., Lahousse, L., Ortega, V. E., Jonsdottir, I., Sin, D. D., Bossé, Y., van den Berge, M., Nickle, D., Quint, J. K., Sayers, I., Hall, I. P., Langenberg, C., Ripatti, S., Laitinen, T., Wu, A. C., Lasky-Su, J., Bakke, P., Gulsvik, A., Hersh, C. P., Hayward, C., Langhammer, A., Brumpton, B., Stefansson, K., Cho, M. H., Wain, L. V., and Tobin, M. D.

Abstract

Background: Some people have characteristics of both asthma and COPD (asthma-COPD overlap), and evidence suggests they experience worse outcomes than those with either condition alone. Research Question: What is the genetic architecture of asthma-COPD overlap, and do the determinants of risk for asthma-COPD overlap differ from those for COPD or asthma? Study Design and Methods: We conducted a genome-wide association study in 8,068 asthma-COPD overlap case subjects and 40,360 control subjects without asthma or COPD of European ancestry in UK Biobank (stage 1). We followed up promising signals (P < 5 × 10 –6) that remained associated in analyses comparing (1) asthma-COPD overlap vs asthma-only control subjects, and (2) asthma-COPD overlap vs COPD-only control subjects. These variants were analyzed in 12 independent cohorts (stage 2). Results: We selected 31 independent variants for further investigation in stage 2, and discovered eight novel signals (P < 5 × 10 –8) for asthma-COPD overlap (meta-analysis of stage 1 and 2 studies). These signals suggest a spectrum of shared genetic influences, some predominantly influencing asthma (FAM105A, GLB1, PHB, TSLP), others predominantly influencing fixed airflow obstruction (IL17RD, C5orf56, HLA-DQB1). One intergenic signal on chromosome 5 had not been previously associated with asthma, COPD, or lung function. Subgroup analyses suggested that associations at these eight signals were not driven by smoking or age at asthma diagnosis, and in phenome-wide scans, eosinophil counts, atopy, and asthma traits were prominent. Interpretation: We identified eight signals for asthma-COPD overlap, which may represent loci that predispose to type 2 inflammation, and serious long-term consequences of asthma.

Published
2022

47. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study

Author

Chupp, G.L., primary, Heaney, L.G., additional, Pelaia, G., additional, Welte, T., additional, Almonacid Sanchez, C., additional, Lee, J.K., additional, Maxwell, A., additional, Price, R.G., additional, Jakes, R.W., additional, Alfonso Cristancho, R., additional, Howarth, P., additional, and Brusselle, G., additional

Published
2022
Full Text
View/download PDF

48. FeNO as a Potential Prognostic and Predictive Marker of Lung Function Decline in Patients with Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA QUEST

Author

Pavord, I.D., primary, Brusselle, G., additional, Jackson, D.J., additional, Brightling, C.E.E., additional, Papi, A., additional, Maspero, J.F., additional, Rabe, K.F., additional, Korn, S., additional, Zhang, M., additional, Djandji, M., additional, Hardin, M., additional, De Prado Gomez, L., additional, Jacob-Nara, J.A., additional, and Rowe, P.J., additional

Published
2022
Full Text
View/download PDF

49. Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Author

Gurnell, M., primary, Domingo Ribas, C., additional, Rabe, K.F., additional, Menzies-Gow, A., additional, Price, D., additional, Brusselle, G., additional, Wechsler, M.E., additional, Xia, C., additional, Djandji, M., additional, Gall, R., additional, Jacob-Nara, J.A., additional, Rowe, P.J., additional, Deniz, Y., additional, and Siddiqui, S., additional

Published
2022
Full Text
View/download PDF

50. ERS statement : a core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations

Author

Mathioudakis, AG, Abroug, F, Agusti, A, Ananth, S, Bakke, P, Bartziokas, K, Beghe, B, Bikov, A, Bradbury, T, Brusselle, G, Cadus, C, Coleman, C, Contoli, M, Corlateanu, A, Corlateanu, O, Criner, GJ, Csoma, B, Emelyanov, A, Faner, R, Fernandez Romero, G, Hammouda, Z, Horváth, P, Huerta Garcia, A, Jacobs, M, Jenkins, C, Joos, G, Kharevich, O, Kostikas, K, Lapteva, E, Lazar, Z, Leuppi, JD, Liddle, C, Linnell, J, López-Giraldo, A, McDonald, VM, Nielsen, R, Papi, A, Saraiva, I, Sergeeva, G, Sioutkou, A, Sivapalan, P, Stovold, E, Wang, H, Wen, F, Yorke, J, Williamson, PR, Vestbo, J, and Jensen, J-U

Subjects
Pulmonary and Respiratory Medicine, LIFE, MEASUREMENT INSTRUMENTS, TIME-COURSE, IMPACT, CHECKLIST, Medicine and Health Sciences, QUESTIONNAIRE, QUALITY, CARE, OBSTRUCTIVE PULMONARY-DISEASE, VALIDATION
Abstract

Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. We have developed a core outcome set, a consensus-based minimum set of important outcomes that we recommend are evaluated in all future clinical trials on exacerbations management, to improve their quality and comparability. COPD exacerbations outcomes were identified through methodological systematic reviews and qualitative interviews with 86 patients from 11 countries globally. The most critical outcomes were prioritised for inclusion in the core outcome set through a two-round Delphi survey completed by 1063 participants (256 patients, 488 health professionals and 319 clinical academics) from 88 countries in five continents. Two global, multi-stakeholder, virtual consensus meetings were conducted to 1) finalise the core outcome set and 2) prioritise a single measurement instrument to be used for evaluating each of the prioritised outcomes. Consensus was informed by rigorous methodological systematic reviews. The views of patients with COPD were accounted for at all stages of the project. Survival, treatment success, breathlessness, quality of life, activities of daily living, the need tor a higher level of care, arterial blood gases, disease progression, future exacerbations and hospital admissions, treatment safety and adherence were all included in the core outcome set. Focused methodological research was recommended to further validate and optimise some of the selected measurement instruments. The panel did not consider the prioritised set of outcomes and associated measurement instruments to be burdensome for patients and health professionals to use.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results